Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company's research and development activities involve small-molecule drugs, and peptides.
Stock Price Prediction
Update at 5:00pm EST
18.476 - 18.606
18.606 - 18.707
17.678 - 17.815
17.815 - 17.922
18.13 - 18.343
18.343 - 18.509
as of: 2019-11-19 4:28:32 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.NKTR has closed above bottom band by 36.2%. Bollinger Bands are 30.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
2019-11-16 Nektar Therapeutics (NASDAQ:NKTR) Price Target Increased to $24.00 by Analysts at Canaccord Genuity Nektar Therapeutics (NASDAQ:NKTR) had its price target raised by Canaccord Genuity from $20.00 to $24.00 in a research report sent to investors on Tuesday, The Fly reports. Canaccord Genuity currently has a buy rating on the biopharmaceutical company’s stock. A number of other analysts also recently issued reports on the stock. BidaskClub downgraded shares of […]
2019-11-11 Nektar Therapeutics Stock Is Rising on Test Data for Cancer Drug Nektar Therapeutics released clinical data that raised hope about a drug-development program that has encountered manufacturing problems.
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.